Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
Status:
RECRUITING
Trial end date:
2027-04-30
Target enrollment:
Participant gender:
Summary
This study will investigate if modulating the tumor microenvironment with biologic agents like XL-092 will have synergistic eect when combined with checkpoint based immunotherapeutic treatment of patients with hepatocellular carcinoma (HCC).